Expand MBX Menu
MBX MENU

MBX Stock Posts


Unusual Option Volume

MBX MBX Biosciences18.85-1.15 (-5.8%)

MBX Biosciences trades 2,922 contracts. News: MBX Biosciences Announces Proposed Public Offering
View Details...
MBX #MBXBiosciences stock declines -2.1% in after hours trading. See the latest news.

After Hours Decliner

MBX MBX Biosciences20.00+10.00+100.0%

After Hours:19.58-0.42 (-2.1%)

MBX Biosciences Announces Proposed Public Offering

Globe NewswireMon, 22-Sep 4:14 PM
MBX #MBXBiosciences stock declines -2.1% in after hours trading. See the latest news.

After Hours Decliner

MBX MBX Biosciences20.00+10.00+100.0%

After Hours:19.58-0.42 (-2.1%)

MBX Biosciences Announces Proposed Public Offering

Globe NewswireMon, 22-Sep 4:14 PM
Unusual Option Volume

MBX MBX Biosciences25.73+15.73 (+157.3%)

MBX Biosciences trades 4,643 contracts. The company has the following event: Conference Call and Webcast to Discuss Avail Phase 2 Trial Results on Sep 22, 2025. News: MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
View Details...
MBX #MBXBiosciences stock increases 37.5% after hours.

After Hours Gainer

MBX MBX Biosciences10.00-0.07-0.7%

After Hours:13.75+3.75 (+37.5%)

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Globe NewswireFri, 19-Sep 4:19 PM
MBX #MBXBiosciences stock increases 26.9% after hours.

After Hours Gainer

MBX MBX Biosciences10.00-0.07-0.7%

After Hours:12.69+2.69 (+26.9%)

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Globe NewswireFri, 19-Sep 4:19 PM
Load Earlier Posts
Market Data Delayed 15 Minutes